Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00182741 · ClinicalTrials.gov registry record · Phase 2
Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00182741 is a Phase 2 study that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 19 participants.
The verdict
NCT00182741, a Phase 2 study, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
RATIONALE: Calcitriol may cause prostate cancer cells to look more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as mitoxantrone and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well giving calcitriol together with mitoxantrone and prednisone works in treating patients with metastatic prostate cancer.
Interventions
- DRUG prednisone
- DIETARY_SUPPLEMENT calcitriol
- DRUG mitoxantrone hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2004-09 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00182741
The ClinicalTrials.gov registry entry for NCT00182741 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which prednisone is the first listed.
NCT00182741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00182741 about?
NCT00182741 is a clinical study titled "Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer". RATIONALE: Calcitriol may cause prostate cancer cells to look more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as mitoxantrone and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from di...
What is the current status of trial NCT00182741?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2004-09. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00182741?
The interventions under investigation include: prednisone (DRUG), calcitriol (DIETARY_SUPPLEMENT), mitoxantrone hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00182741?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.